CIS-DIAMMINEDICHLOROPLATINUM II
Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hycamtin National Cancer Institute (NCI) | Phase 1 | CC |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →